Motives for reporting adverse drug reactions by patient-reporters in the Netherlands by van Hunsel, Florence et al.
PHARMACOEPIDEMIOLOGY AND PRESCRIPTION
Motives for reporting adverse drug reactions
by patient-reporters in the Netherlands
Florence van Hunsel & Christine van der Welle &
Anneke Passier & Eugène van Puijenbroek &
Kees van Grootheest
Received: 12 April 2010 /Accepted: 6 July 2010 /Published online: 24 July 2010
# The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract
Aim The aim of this study was to quantify the reasons and
opinions of patients who reported adverse drug reactions
(ADRs) in the Netherlands to a pharmacovigilance centre.
Method A web-based questionnaire was sent to 1370
patients who had previously reported an ADR to a
pharmacovigilance centre. The data were analysed using
descriptive statistics, χ
2 tests and Spearman’s correlation
coefficients.
Results The response rate was 76.5% after one reminder.
The main reasons for patients to report ADRs were to share
their experiences (89% agreed or strongly agreed), the
severity of the reaction (86% agreed or strongly agreed to
the statement), worries about their own situation (63.2%
agreed or strongly agreed) and the fact the ADR was not
mentioned in the patient information leaflet (57.6% agreed
or strongly agreed). Of the patient-responders, 93.8%
shared the opinion that reporting an ADR can prevent
harm to other people, 97.9% believed that reporting
contributes to research and knowledge, 90.7% stated that
they felt responsible for reporting an ADR and 92.5%
stated that they will report a possible ADR once again in
the future.
Conclusion The main motives for patients to report their
ADRs to a pharmacovigilance centre were the severity of
the ADR and their need to share experiences. The high
level of response to the questionnaire shows that patients
are involved when it comes to ADRs and that they are also
willing to share their motivations for and opinions about the
reporting of ADRs with a pharmacovigilance centre.
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Introduction
An increasing number of countries are incorporating the
direct reporting of adverse drug reactions (ADRs) by
patients into pharmacovigilance systems [1]. Consequently,
knowledge of the factors influencing patient reporting to
pharmacovigilance systems on a day-to-day basis has been
increasing in recent years [1–4].
The organization responsible for the management of the
spontaneous reporting system for ADRs in the Netherlands is
the Netherlands Pharmacovigilance Centre Lareb, on behalf
of the Medicines Evaluation Board. Not only healthcare
professionals and marketing authorization holders are able to
report ADRs directly to Lareb; since April 2003, patients can
also report ADRs directly to Lareb. Patients can report
ADRs through an electronic reporting form available on the
Lareb website that is identical, in terms of content, to that
used by healthcare professionals. Several mandatory fields in
this form ensure the completeness of the information before
it can be sent to the pharmacovigilance centre. In rare cases
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paper reporting form can be sent upon request. Patients’ and
healthcare professionals’ reports are coded according to
MedDRA (Medical Dictionary for Regulatory Activities)
terminology, individually assessed by trained assessors and
stored in the same database. All reporters, both patients and
healthcare professionals, receive feedback information on
their reported ADR(s) [2].
In 2008, the Netherlands Pharmacovigilance Centre
Lareb published their experiences on 3 years of patient
reporting [2]. The Centre reported that patients’ reports
contained different information than those of healthcare
professionals with respect to categories of seriousness and
outcome of the reported ADRs [2]. When patients’ and
healthcare professionals’ ADR reports on statins were
compared following media attention, patient reports were
found to provide additional information on the different
categories of adverse reactions, the impact of ADRs on
daily life and the patient–health professional relationship
[3]. In a study carried out in Denmark, patients were also
found to report different categories of ADRs for different
types of medicines compared to other reporters [4]. Based
on these results, the authors of this study concluded that
consumers should be actively included in systematic drug
surveillance systems. A patient’s own firsthand report of
his/her experiences with drugs can capture side effects that
clinicians might miss [5, 6]. According to Foster et al.
‘patient-reporting can be an important source of informa-
tion about side effects in the context of real-life clinical
practice’ [7].
The motivations and attitudes of healthcare professionals
towards ADR reporting to a pharmacovigilance centre have
been studied extensively [8–20]. In contrast, the reasons
why patients report ADRs are less well known. As Aagaard
et al. [4] noted, consumers’ experiences with and perspec-
tives on ADRs should be further studied. A qualitative
study involving guided interviews with 21 patients in the
Netherlands was performed to gain insight into the
motivations of patients who report ADRs to a pharmaco-
vigilance centre [21]. Most patients expressed altruistic
motives, but also the severity of the ADR and the need for
extra information about the ADR were mentioned as
motives for reporting.
The aim of this study is to quantify both the reasons for
reporting ADRs and the opinions of patients regarding the
reporting of ADRs to a pharmacovigilance centre in the
Netherlands.
Method
Data from interviews investigating patients’ motives for
reporting ADRs [21] were used to develop a questionnaire
that could be sent to a large group of patient-reporters.
Questionnaires were web-based and sent via the online web
service SurveyMonkey [22].
Study population
The target population comprised patients who reported an
ADR to the Netherlands Pharmacovigilance Centre Lareb
between January 1, 2008 and March 1, 2009. A total of
1503 case reports of ADRs were reported by patients
during this period. Of these, 1440 patients reported by
means of the electronic reporting form on the Lareb
website, which is the preferred reporting method of the
pharmacovigilance centre, and the e-mail address of each of
these 1440 reports was selected. As some patients had
reported several times, their e-mail addresses could be
present twice or more in the list (but with different report
numbers). The final list thus comprised 1370 different e-mail
addresses of patient-reporters, who were then approached for
inclusion in the study.
Questionnaire
A list of all categories of quotes from an earlier qualitative
study [21] was compiled with the support of QSR NVivo
ver. 8.0.264.0, a software programme for ordering qualita-
tive data [23]. These categories were rephrased to state-
ments (with rating scales) as questionnaire items.
Categories of quotes from the interviews that were much
alike were combined in order to reduce the time needed for
answering the questionnaire as much as possible. The
statements were divided into ‘Reasons’ and ‘Opinions’. The
questionnaire items could be rated on a five-point Likert
scale (strongly agree to strongly disagree) [24], where the
middle position was labelled ‘neutral’ to reflect a neutral
position, and not an inability to answer the question. The
first theme contained statements relating to reasons for
reporting an ADR. Next to the response options on the
possible reasons to report an ADR, was an ‘Other’ option
along with a free text area for ‘please specify’. The second
theme included statements on the opinions of patients with
respect to reporting an ADR. Patients were also asked if
they would report a possible ADR again in the future.
Possible ‘Reasons’ and ‘Opinions’ are given in Table 1
The questionnaire addressed a number of demographic
aspects, including gender, age (<18 years, 18–35 years, 36–
64 years, >65 years), level of education (primary school,
secondary school, vocational education, higher professional
education, academic education) and possible membership
in a patients’ association. Patients who are a member of a
patient organization may possess more information on the
reporting of ADRs to a pharmacovigilance centre and also
may have other motives or opinions on this subject.
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The web-based survey was first tested in a small group of
field testers and subsequent sent to the selected e-mail
addresses on March 23, 2009. Two weeks later (April 6,
2009), a reminder was sent to all non-responders. Collec-
tion of responses was finished after 1 month (April 24,
2009). The link in the invitation e-mail was uniquely tied to
the survey and the respondent’s e-mail address. Therefore,
the message could not be forwarded by respondents, and
only one response per e-mail address was allowed. This
also implied that random surfers on the Internet could not
reach the online survey.
Data analysis
Descriptive statistics provided an overview of the patient
characteristics, the reasons for reporting ADRs and the
opinions of patients on reporting ADRs.
A Pearson Chi-square (χ
2) test was performed to detect
significant differences in motives and opinions between
patients who were members of a patient organization and
those who were not and in differences in answers between
men and women. Significance was based on a two-sided
χ
2-test and significance was set at p<0.05.
Correlations were calculated to measure possible rela-
tionships between two or more statements. Because the data
were measured at the ordinal level (Likert-scale), Spear-
man’s correlation coefficient (r) was used in this analysis.
In this study, a correlation was considered strong if r>0.7,
moderate if r>0.4 and<0.7 and weak if r<0.4 [25]. Data
were analysed using the statistical software programme
SPSS Statistics, ver. 17.0 (SPSS, Chicago, IL).
The answers to the open question on the reasons to report
(the question ‘Other, please specify…’) were specified by
two researchers independently (FvH and CvdW) and
categorized. These responses to the open question were then
compared with the responses to the statements in the
questionnaire to identify possible new motives for reporting
that were not covered by the questionnaire.
Results
Response
A total number of 1370 potential participants were
approached by e-mail, of which 57 e-mails were
undeliverable. Of the remaining 1313 patients who received
an e-mail, 1005 completed and returned the questionnaire,
Table 1 Statements used in the questionnaire to assess the reasons for reporting an adverse drug reaction (ADR) and the opinions of patients
regarding the reporting of an ADR
Reasons
I wanted extra information
The adverse drug reaction was severe
It was difficult to discuss the adverse drug reaction with my medical practitioner or pharmacist
The possibility for reporting an adverse drug reaction just exists
I wanted to be heard
Someone else pointed the possibility for reporting an adverse drug reaction
I was angry about the situation
I wanted action to be taken
I wanted to share my experiences
The adverse drug reaction was not mentioned in the patient information leaflet
I was worried about my own situation
Opinions
Reporting an adverse drug reaction can prevent harm to other people
I felt responsible for reporting an adverse drug reaction
Reporting an adverse drug reaction that is already mentioned in the patient information leaflet is useless
I only report an adverse drug reaction if it is serious
Reporting an adverse drug reaction contributes to research and knowledge
I report an adverse drug reaction if it is not mentioned in the patient information leaflet
I benefit from reporting an adverse drug reaction
Reporting an adverse drug reaction contributes to improvement of drugs
I report an adverse drug reaction if it is unexpected
In the future I will report a possible adverse drug reaction once again
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responses were six responses by healthcare professionals
whosee-mailaddresseshadbeenselectedbecausetheyhadby
mistake reported an ADR using the patient reporting form
instead of the healthcare professional form. These six
responses were not taken into account, which resulted in 999
useful responses for the analysis. The responses to the
questionnaire are shown in Fig. 1. The characteristics of the
patient-reporters are given in Table 2.
Reasons to report an ADR
An overview of the responses on the reasons for reporting
ADRs is given in Table 3.
The main reasons for patients to report ADRs were to share
their experiences (89% agreed or strongly agreed), the severity
ofthereaction(86%agreedorstronglyagreedtothestatement),
worries about their own situation (63.2% agreed or strongly
agreed) and the fact the ADR was not mentioned in the patient
information leaflet (57.6% agreed or strongly agreed).
Responses to the open question
The open text field in the questionnaire for ‘Other reasons for
reporting’ was filled in by 228 respondents. The reasons to
Fig. 1 Flowchart of the
respondents to the questionnaire
Table 2 Respondent characteristics
Variable Percentage (n)
Gender
Male 33.4% (334)
Female 66.6% (665)
Age
<18 years 0.2% (2)
18-35 year 16.1% (161)
36-64 year 69.1% (690)
>65 years 14.6% (146)
Education
Primary school 1.1% (11)
Secondary school 10.8% (108)
Vocational education 33.0% (330)
Higher professional education 37.1% (371)
Academic 17.9% (179)
Member of patients association
a
Yes 24.7% (247)
No 75.1% (750)
a997 responses, 2 not reported
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open question are ‘For other people’ (n=33), ‘Medical
practitioner or pharmacist does not acknowledge the problem
or take it seriously’ (n=27), ‘ADR was severe’ (n=21) and
‘Comments on patient information leaflet’ (n=20). The other
responses to the open question (n =127) could not be
grouped together easily because of a large variety of subjects.
The responses to the open question were compared to
the statements in the questionnaire. The reason ‘Medical
practitioner or pharmacist does not acknowledge the
problem or take it seriously’ was not included as a
statement in this survey. Apparently, the respondents
considered this a different reason than the statement ‘It
was difficult to discuss the adverse drug reaction with my
medical practitioner or pharmacist’.
Other findings
Among the patient-responders, 93.8% shared the opinion that
reporting an ADR can prevent harm to other people, 97.9%
believedthatreportingcontributestoresearchandknowledge,
90.7% stated that they felt responsible for reporting an ADR
and92.5% patientsstatedthattheywillreporta possibleADR
once again in the future. The opinions of the patient-
responders on reporting ADRs are shown in Table 4.
There was no statistically significant differences in the
answers between men and women for all statements (χ
2 test
p>0.05), with the exception of the motive ‘I was worried
about my own situation’ (χ
2 test p=0.022): 70% of the men
were worried about their situation in comparison with
59.8% of the women.
Membership in a patient organization was compared with
the answers on the statements. There was no statistically
significant difference in the answers (agree, neutral, disagree)
between members or non-members for all statements (χ
2 tests
p>0.05), except for the opinion ‘In the future I will report a
possible adverse drug reaction once again’ (χ
2 test p=0.036):
95.5% of the members of a patient organization agreed to
this statement compared to 91.3% of non-members.
The correlation coefficients between the reasons for
reporting ADRs, between the opinions and between the
reasons and opinions were mostly moderate or weak (r>0.4
<0.7 or r<0.4). The highest correlation coefficient (r) was
0. 616 (between Reason 7 ‘I was angry about the situation’
and Reason 8 ‘I wanted action to be taken’).
Discussion
Findings
This study confirms the findings of the previous qualitative
interviews [21].Based on the results of the completed
questionnaires, patients report ADRs for various reasons,
of which the most important are a severe ADR, wanting to
share experiences, worry about the ADR in a personal
context and the ADR not being mentioned in the patient
information leaflet. Patients also believe that reporting an
ADR can prevent harm to other people and that reporting
contributes to research and knowledge. Most patients stated
that they felt responsible for reporting an ADR.
An additional motive for reporting ADRs, derived from
the open question, was ‘My medical practitioner or
pharmacist does not acknowledge the problem or take it
seriously’. This motive was mentioned during the qualita-
tive interviews as well [21]. It is likely that the wording of
Table 3 Motives for reporting ADRs
Motive Strongly agree Agree Neutral Disagree Strongly disagree
I wanted extra information 19.6% (196) 25.2% (252) 22.2% (222) 17.9% (179) 15.0% (150)
The adverse drug reaction was severe 53.7% (536) 32.5% (325) 8.2% (82) 3.5% (35) 2.1% (21)
It was difficult to discuss the adverse drug reaction
with my medical practitioner or pharmacist
6.0% (60) 9.3% (93) 15.8% (158) 34.5% (345) 34.3% (343)
The possibility for reporting an adverse drug reaction just exists 34.7% (347) 38.0% (380) 17.9% (179) 5.6% (56) 3.7% (37)
I wanted to be heard 25.1% (251) 28.4% (284) 26.4% (264) 12.7%(127) 7.3% (73)
Someone else pointed the possibility for reporting an
adverse drug reaction
14.9% (149) 17.1% (171) 14.2% (142) 28.7% (287) 25.0% (250)
I was angry about the situation 20.7% (207) 18.9% (189) 20.5% (205) 22.7% (227) 17.1% (171)
I wanted action to be taken 27.3% (273) 31.0% (310) 23.6% (236) 11.0% (110) 7.0% (70)
I wanted to share my experiences 48.1% (481) 40.9% (409) 6.3% (63) 2.8% (28) 1.8% (18)
The adverse drug reaction was not mentioned in the
patient information leaflet
33.2% (332) 24.4% (244) 17.5% (175) 17.1% (171) 7.7% (77)
I was worried about my own situation 32.5% (325) 30.7% (307) 17.5% (175) 12.2% (122) 7.0% (70)
Data on motives are given as the percentage of total responses, with the frequency (n) of the response given in parenthesis
Most frequently reported response is given in bold
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the healthcare professional (reason 3) was not clear enough in
emphasizingthe acknowledgementofthemedical practitioner
or pharmacist instead of the difficulty in discussing the ADR.
The severity of an ADR as a motive for reporting does not
necessarily mean that the patient suffered from an ADR that
was serious according to international criteria [26]. Medical
seriousness may differ from patients’ views on what
constitutes a serious problem [27].
In 2009, 27.0% of the Dutch population between the age
of 15 and– 65 years had achieved an educational level of
higher professional education/academic [28]. In compari-
son, 55% of the participants in this study had a high level of
education. The high level of education among the respond-
ents is not surprising considering that this group may be
better informed about healthcare in general and the
possibility to report ADRs.
Two-thirds of the respondents to the questionnaire were
female. This is almost the same proportion as in the whole
population of patient-reporters in our research period (1440
in total, 63.6% women). This is also in line with a previous
study by De Langen et al. [2], who found that 63% of the
patient-reporters were female. In 2009, 50.5% of the Dutch
population were female. This difference in the percentages
could possibly be a result of women experiencing a higher
incidence of ADRs than men [29] and/or of women being
more eager to report ADRs to a pharmacovigilance centre.
However, there were no differences in answers between
men and women, except for the answers to the reason
‘Being worried about own situation’.
Elderly people are more at risk of developing an ADR
[30], so it is important that the motives and opinions of this
group are also taken into account. Of the respondents to the
questionnaire, 14.6% were older than 65 years; of this latter
group, less then 2% of the respondents were older than
80 years. This corresponds fairly well to the demographic
structure of the Dutch population in 2009: 11.2% were aged
65–80 years and 3.8% were older than 80 years [28].
Comparison to other studies
To the best of our knowledge, the Netherlands pharmaco-
vigilance centre is the only such centre to have published
studies on patient’s motives for reporting ADRs to a
pharmacovigilance centre [21, 31]. During the first 1-year
trial period of patient reporting in the Netherlands, patients
were asked why they reported an ADR to the pharmaco-
vigilance centre instead of to their healthcare professional.
Of the respondents, 23% stated that they felt their
complaints would not be taken seriously elsewhere, and
22% had already reported the ADR to a healthcare
professional—with no result [31]. In a qualitative study
with 21 patients, almost all patients had multiple motives
for reporting. Among the altruistic motives were preventing
harm to other patients, making the ADR publicly known,
increasing medical knowledge and wanting to improve the
patient information leaflet. Personal motives to report an
ADR included wanting more information about the ADR,
indicating that the ADR was too severe not to report, being
angry or wanting confirmation of their ADR [21]. These
results have been generalized and quantified in a large
group in the present study.
Several studies have been conducted with the aim of
investigating their motivations of healthcare professionals
Table 4 Opinions on reporting ADRs
Opinions Strongly agree Agree Neutral Disagree Strongly disagree
Reporting an adverse drug reaction can prevent
harm to other people
61.1% (610) 32.7% (327) 4.1% (41) 1.6% (16) 0.5% (5)
I felt responsible for reporting an adverse drug reaction 50.5% (504) 40.2% (402) 8.1% (81) 1.0% (10) 0.2% (2)
Reporting an adverse drug reaction that is already mentioned
in the patient information leaflet is useless
13.9% (139) 20.1% (201) 18.8% (188) 31.7% (317) 15.4% (154)
I only report an adverse drug reaction if it is serious 24.6% (246) 34.5% (345) 14.9% (149) 20.5% (205) 5.4% (54)
Reporting an adverse drug reaction contributes to
research and knowledge
60.9% (608) 37.0% (370) 1.8% (18) 0 0.3% (3)
I report an adverse drug reaction if it is not mentioned
in the patient information leaflet
39.5% (395) 35.2% (352) 14.8% (148) 8.7% (87) 1.7% (17)
I benefit from reporting an adverse drug reaction 11.7% (117) 23.3% (233) 36.2% (362) 19.8% (198) 8.9% (89)
Reporting an adverse drug reaction contributes to
improvement of drugs
41.4% (414) 43.7% (437) 13.2% (132) 1.2% (12) 0.4% (4)
I report an adverse drug reaction if it is unexpected 30.2% (302) 41.1% (411) 17.0% (170) 9.0% (90) 2.6% (26)
In the future I will report a possible adverse drug
reaction once again
47.9% (479) 44.4% (444) 6.7% (67) 0.3% (3) 0.6% (6)
Data on motives are given as the percentage of total responses, with the frequency (n) of the response given in parenthesis
Most frequently reported response is given in bold
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20]. Hasford et al. [12] and Ekman et al. [9] indicated that
the severity of the reaction, unusual reaction of the reporter to
the drug and a reaction caused by a new drug were the main
reasonsmotivatinghealthcareprofessionalsto report ADRs. In
the study by Bäckström et al. [20], three-quarters of the
respondents stated that the severity of the reaction was the
main factor determining whether a suspected ADR was
reported or not. Biriell et al. [16] found the following motives
as positive reasons for physicians and pharmacists to report
an ADR: desire to contribute to medical knowledge, reaction
previously unknown to the reporter, reaction to new drug,
desire to report all significant reactions, known association
between drug and reaction and severity of reaction.
Some of the motives found for healthcare professionals
are also important reasons for patients to report, such as
severity of the reaction and wanting to contribute to
medical knowledge.
Validity of the study design
The statements in the questionnaire were based upon
qualitative interviews with patients that were aimed at
increasing the validity of the survey instrument [32]. The
response rate to the questionnaire was more than 76.5%,
which is high compared to some other studies on motivations
for (not) reporting ADRs [9, 20]. The high response rate
increases the validity of the results found in this study.
There are also some limitations to this study. The study
population comprised patients who had already reported an
ADR to the pharmacovigilance centre in the Netherlands,
which is a selected population. One could assume that
patients who are interested in their drug treatment and
especially those who had already experienced an ADR
would be more willing to answer this type of questionnaire.
We did not include the motives and opinions of patients
who experienced an ADR but who choose not report this to
the pharmacovigilance centre.
Because 96% of our target study population consisted of
patients who had previously reported an ADR through the
online reporting form, it was possible to use a web-based
questionnaire. Most people in the Netherlands have access to
the Internet: in 2009, 91% of the Dutch population younger
than 65 years had such access according to Statistics Nether-
lands [28]. However, selection bias cannot be excluded. In
the age category 65–75 years, Statistics Netherlands reported
that in 2009 only 64% of the population had Internet access,
and it had no specific data on Internet access for age groups
older than 75 years. Of the responders in the 2009 survey,
91% up to the age of 55 years had used the Internet in the 3
months preceding the survey. In comparison, for people aged
55–65 years this was 82% and for people aged 65–75 years,
53% [28]. Patients who did not use the electronic reporting
form (n=63) were excluded from this study, but it is possible
that other motives were present in this group. The
pharmacovigilance centre accepts consumers reporting for
relatives; for example, children with access to the Internet
could report for an elderly parent.
The use of the Internet is also correlated to the level of
education [28], which may also have increased selection
bias. The level of education in the Netherlands is higher than
the average level in the European Union (EU-27 countries),
with 27% of the Dutch population educated to the highest
level versus 19.1% of the EU-27 population [33]. In 2009,
an average of 65% of the households of the EU-27 countries
had access to the Internet, which is considerably lower than
the 90% in the Netherlands [33]. In fact, the percentage of
access to the Internet in the Netherlands is the highest of all
European countries [33]. Therefore, the use of a web-bases
questionnaire might not be feasible in all countries in the
same manner as in the Netherlands.
Conclusions
Based on the results of our questionnaire survey, the main
motives for patients to report an ADRs to a national
pharmacovigilance centre were the severity of the ADR and
the need to share experiences. Altruistic motives are
reflected by the high responses to the statements ‘Reporting
an adverse drug reaction can prevent harm to other people’,
‘I felt responsible for reporting an adverse drug reaction’
and ‘Reporting an adverse drug reaction contributes to
research and knowledge’. There was only a small group of
patients who felt that they reported an ADR for personal
benefit. The high level of response to the questionnaire
shows that patients are involved when it comes to ADRs and
also willing to share their motivations for and opinions about
the reporting of ADRs with the pharmacovigilance centre.
More than 90% of the patients who had already reported an
ADR once agreed with the statement ‘In the future I will
report a possible adverse drug reaction once again’.
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